William Cooper Selected Research

Granisetron (Kytril)

6/2016	APF530 (granisetron injection extended-release) in a three-drug regimen for delayed CINV in highly emetogenic chemotherapy.
2/2016	Randomized phase III trial of APF530 versus palonosetron in the prevention of chemotherapy-induced nausea and vomiting in a subset of patients with breast cancer receiving moderately or highly emetogenic chemotherapy.
9/2015	Slow-release granisetron (APF530) versus palonosetron for chemotherapy-induced nausea/vomiting: analysis by American Society of Clinical Oncology emetogenicity criteria.
3/2015	Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial.
2/2015	Sustained antiemetic responses with APF530 (sustained-release granisetron) during multiple cycles of emetogenic chemotherapy.
1/2015	Pharmacokinetics, safety, and efficacy of APF530 (extended-release granisetron) in patients receiving moderately or highly emetogenic chemotherapy: results of two Phase II trials.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

William Cooper Research Topics

Disease

6	Nausea 06/2016 - 01/2015
6	Vomiting 06/2016 - 01/2015
1	Breast Neoplasms (Breast Cancer) 02/2016
1	Neoplasms (Cancer) 02/2015
1	Injection Site Reaction 01/2015
1	Erythema 01/2015
1	Starvation 06/2014
1	Hypertension (High Blood Pressure) 11/2004
1	Stroke (Strokes) 11/2004
1	Albuminuria 11/2004
1	Cardiovascular Diseases (Cardiovascular Disease) 11/2004
1	Diabetic Nephropathies (Diabetic Nephropathy) 11/2004
1	Heart Failure 11/2004

Drug/Important Bio-Agent (IBA)

6	Granisetron (Kytril)FDA LinkGeneric 06/2016 - 01/2015
4	Palonosetron (Aloxi)FDA Link 02/2016 - 02/2015
1	AnthracyclinesIBA 02/2016
1	Delayed-Action PreparationsIBA 03/2015
1	AntiemeticsIBA 01/2015
1	OligosaccharidesIBA 06/2014
1	CarbohydratesIBA 06/2014
1	Serum AlbuminIBA 11/2004
1	AlbuminsIBA 11/2004
1	CreatinineIBA 11/2004
1	Irbesartan FDA LinkGeneric 11/2004

Therapy/Procedure

6	Drug Therapy (Chemotherapy) 06/2016 - 01/2015
1	Therapeutics 01/2015
1	Surgical Amputation (Amputations) 11/2004